Bruce Jancin writing in Rheumatology News reported
on a study involving 603 patients with heart disease including heart failure. 103 patients
were taking allopurinol while 500 were not. In retrospectively evaluating data, it was
clear that allopurinol reduced the risk of atrial fibrillation in the setting of heart
failure and also reduced the risk of left ventricular hypertrophy- an enlarged heart-
in patients with Type 2 diabetes. The study was conducted at the Miami VA and presented
at the meeting of the American College of Cardiology. Comment: An old drug with new tricks.